Davide Ciardiello, Erika Martinelli, Teresa Troiani, Gianluca Mauri, Daniele Rossini, Giulia Martini, Stefania Napolitano, Vincenzo Famiglietti, Sara Del Tufo, Gianluca Masi, Daniele Santini, Antonio Avallone, Filippo Pietrantonio, Sara Lonardi, Massimo Di Maio, Maria Giulia Zampino, Nicola Fazio, Alberto Bardelli, Salvatore Siena, Chiara Cremolini, Andrea Sartore-Bianchi, Fortunato Ciardiello
IMPORTANCE: The available evidence regarding anti-epidermal growth factor receptor (EGFR) inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) is derived from small retrospective and prospective studies. OBJECTIVE: To evaluate the efficacy of anti-EGFR rechallenge in patients with refractory ctDNA RAS/BRAF wt mCRC. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial used a pooled analysis of individual patient data from patients with RAS/BRAF wt ctDNA mCRC enrolled in 4 Italian trials (CAVE, VELO, CRICKET, and CHRONOS) and treated with anti-EGFR rechallenge between 2015 and 2022 (median [IQR] follow-up, 28...
April 1, 2024: JAMA Network Open